| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | DCP2 |
| Uniprot No | Q8IU60 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-385aa |
| 氨基酸序列 | METKRVEIPGSVLDDLCSRFILHIPSEERDNAIRVCFQIELAHWFYLDFY MQNTPGLPQCGIRDFAKAVFSHCPFLLPQGEDVEKVLDEWKEYKMGVPTY GAIILDETLENVLLVQGYLAKSGWGFPKGKVNKEEAPHDCAAREVFEETG FDIKDYICKDDYIELRINDQLARLYIIPGIPKDTKFNPKTRREIRNIEWF SIEKLPCHRNDMTPKSKLGLAPNKFFMAIPFIRPLRDWLSRRFGDSSDSD NGFSSTGSTPAKPTVEKLSRTKFRHSQQLFPDGSPGDQWVKHRQPLQQKP YNNHSEMSDLLKGKKCEKKLHPRKLQDNFETDAVYDLPSSSEDQLLEHAE GQPVACNGHCKFPFSSRAFLSFKFDHNAIMKILDL |
| 预测分子量 | 68 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于DCP2重组蛋白的3篇参考文献示例(注：文献为假设性概括，实际研究中请以具体论文为准)：
---
1. **标题**: *"Recombinant DCP2 Protein Exhibits Decapping Activity in vitro: Functional Characterization of the Human mRNA Decapping Enzyme"*
**作者**: Smith A, et al.
**摘要**: 本研究通过在大肠杆菌中表达并纯化重组人源DCP2蛋白，证明其具有特异性mRNA脱帽酶活性。体外实验表明，DCP2与辅助因子DCP1结合后可显著增强其水解mRNA 5'端帽子结构的能力，揭示了其在mRNA降解通路中的核心作用。
---
2. **标题**: *"Structural Insights into DCP2 Recruitment by the LSM Complex in mRNA Decay"*
**作者**: Jones B, et al.
**摘要**: 通过X射线晶体学解析了重组DCP2蛋白与LSM复合物的结合结构，发现DCP2的N端结构域直接与LSM1-7环状复合物互作，阐明了脱帽酶在细胞质加工小体(P-body)中靶向mRNA的分子机制。
---
3. **标题**: *"Regulation of Recombinant DCP2 Activity by Post-Translational Modifications in Cancer Cells"*
**作者**: Chen L, et al.
**摘要**: 研究利用昆虫细胞表达系统获得高纯度重组DCP2蛋白，发现其在肿瘤细胞中受磷酸化修饰(如AKT激酶介导的Ser237位点)调控，修饰后脱帽酶活性降低，导致特定致癌mRNA稳定性增加，促进癌细胞增殖。
---
(注：以上文献为示例，实际引用需以真实发表的论文为准。)
**Background of DCP2 Recombinant Protein**
DCP2 (Decapping Enzyme 2) is a critical RNA-binding protein involved in mRNA metabolism, particularly in the removal of the 5' cap structure, a key step in eukaryotic mRNA decay. As a member of the Nudix hydrolase family, DCP2 catalyzes the hydrolysis of the m7GpppN cap, releasing m7GDP and uncapped mRNA, which is then rapidly degraded by exonucleases. This decapping process is tightly regulated and serves as a pivotal control point in post-transcriptional gene expression, influencing cellular responses to stress, development, and disease.
The recombinant DCP2 protein is engineered to study its enzymatic activity, structure, and interactions in vitro. Typically expressed in systems like *E. coli* or mammalian cells, the purified protein retains conserved functional domains, including the catalytic Nudix motif and regulatory regions that mediate interactions with co-factors such as DCP1. Edc4. and the LSM1-7 complex. These partnerships are essential for forming the active decapping complex, which integrates signals from mRNA surveillance pathways (e.g., nonsense-mediated decay).
Research using recombinant DCP2 has elucidated its role in cellular homeostasis and disease. Dysregulation of DCP2 is linked to neurological disorders, viral infections, and cancer, where aberrant mRNA turnover impacts cell proliferation or survival. For instance, reduced DCP2 activity correlates with stabilized oncogenic transcripts in certain cancers, highlighting its potential as a therapeutic target. Structural studies using recombinant proteins have also revealed mechanisms of catalysis and inhibition, aiding in drug discovery.
In summary, DCP2 recombinant protein serves as a vital tool for dissecting mRNA decay pathways and exploring interventions in diseases driven by disrupted RNA dynamics. Its study bridges molecular biology and translational research, offering insights into RNA-based regulation.
在生物科技领域，蛋白研发与生产是前沿探索的关键支撑。艾普蒂作为行业内的创新者，凭借自身卓越的研发实力，每年能成功研发 1000 多种全新蛋白，在重组蛋白领域不断突破。 在重组蛋白生产过程中，艾普蒂积累了丰富且成熟的经验。从结构复杂的跨膜蛋白，到具有特定催化功能的酶、参与信号传导的激酶，再到用于免疫研究的病毒抗原，艾普蒂都能实现高效且稳定的生产。 这一成就离不开艾普蒂强大的技术平台。我们构建了多元化的重组蛋白表达系统，昆虫细胞、哺乳动物细胞以及原核蛋白表达系统协同运作。不同的表达系统各有优势，能够满足不同客户对重组蛋白的活性、产量、成本等多样化的需求，从而提供高品质、低成本的活性重组蛋白。 艾普蒂提供的不只是产品，更是从源头到终端的一站式解决方案。从最初的基因合成，精准地构建出符合要求的基因序列，到载体构建，为蛋白表达创造适宜的环境，再到蛋白质表达和纯化，每一个环节都严格把控。我们充分尊重客户的个性化需求，在表达 / 纯化标签的选择、表达宿主的确定等方面，为客户量身定制专属方案。 同时，艾普蒂还配备了多种纯化体系，能够应对不同特性蛋白的纯化需求。这种灵活性和专业性，极大地提高了蛋白表达和纯化的成功率，让客户的研究项目得以顺利推进，在生物科技的探索道路上助力每一位科研工作者迈向成功。
艾普蒂生物自主研发并建立综合性重组蛋白生产和抗体开发技术平台，包括： 哺乳动物细胞表达平台：利用哺乳动物细胞精准修饰蛋白，产出与天然蛋白相似的重组蛋白，用于药物研发、细胞治疗等。 杂交瘤开发平台：通过细胞融合筛选出稳定分泌单克隆抗体的杂交瘤细胞株，优化后的技术让抗体亲和力与特异性更高，应用于疾病诊断、免疫治疗等领域。 单 B 细胞筛选平台：FACS 用荧光标记和流式细胞仪快速分选特定 B 细胞；Beacon® 基于微流控技术，单细胞水平捕获、分析 B 细胞，挖掘抗体多样性，缩短开发周期。 凭借这些平台，艾普蒂生物为客户提供优质试剂和专业 CRO 技术服务，推动生物科技发展。
艾普蒂生物在重组蛋白和天然蛋白开发领域经验十分丰富，拥有超过 2 万种重组蛋白的开发案例。在四大重组蛋白表达平台的运用上，艾普蒂生物不仅经验老到，还积累了详实的成功案例。针对客户的工业化生产需求，我们能够定制并优化实验方案。通过小试探索、工艺放大以及条件优化等环节，对重组蛋白基因序列进行优化，全面探索多种条件，精准找出最契合客户需求的生产方法。 此外，公司还配备了自有下游验证平台，可对重组蛋白展开系统的质量检测与性能测试，涵盖蛋白互作检测、活性验证、内毒素验证等，全方位保障产品质量。 卡梅德生物同样重视蛋白工艺开发，确保生产出的蛋白质具备所需的纯度、稳定性与生物活性，这对于保障药物的安全性和有效性起着关键作用 ，与艾普蒂生物共同推动着行业的发展。
×
